Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction
NCT02275338
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
52
Enrollment
INDUSTRY
Sponsor class
Conditions
Intestinal Obstruction
Interventions
DRUG:
Lanreotide Autogel
Sponsor
Ipsen